[Current issues on gastroesophageal reflux disease].

Gastroesophageal reflux disease (GERD) is one of the most common problems in gastrointestinal disorders. With the increase in our understanding on the pathophysiology of GERD along with the development of proton pump inhibitors, the diagnostic and therapeutic approaches to GERD have changed dramatically over the past decade. However, GERD still poses a problem to many clinicians since the spectrum of the disease has evolved to encompass more challenging presentations such as refractory GERD and extraesophageal manifestations. This has led to significant confusion regarding the optimal approach to these patients. This article aims to discuss current issues on GERD.

[1]  V. Velanovich,et al.  Surgical treatment of GERD: where have we been and where are we going? , 2014, Gastroenterology clinics of North America.

[2]  C. Gyawali,et al.  Esophageal manometry in gastroesophageal reflux disease. , 2014, Gastroenterology clinics of North America.

[3]  G. Boeckxstaens,et al.  Pathophysiology of gastroesophageal reflux disease. , 2014, Gastroenterology clinics of North America.

[4]  G. Boeckxstaens,et al.  An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  L. Swanstrom,et al.  Preoperative diagnostic workup before antireflux surgery: an evidence and experience-based consensus of the Esophageal Diagnostic Advisory Panel. , 2013, Journal of the American College of Surgeons.

[6]  E Soffer,et al.  Long-term results of electrical stimulation of the lower esophageal sphincter for the treatment of gastroesophageal reflux disease , 2013, Endoscopy.

[7]  M. Vela,et al.  Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease , 2013, The American Journal of Gastroenterology.

[8]  P. Shekelle,et al.  Upper Endoscopy for Gastroesophageal Reflux Disease: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians , 2012, Annals of Internal Medicine.

[9]  G. Karamanolis,et al.  Selective Serotonin Reuptake Inhibitors for the Treatment of Hypersensitive Esophagus: A Randomized, Double-Blind, Placebo-Controlled Study , 2012, The American Journal of Gastroenterology.

[10]  Hyojin Park,et al.  [Updated guidelines 2012 for gastroesophageal reflux disease]. , 2012, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.

[11]  C. Gyawali,et al.  Analysis of Intersegmental Trough and Proximal Latency of Smooth Muscle Contraction Using High-resolution Esophageal Manometry , 2012, Journal of clinical gastroenterology.

[12]  G. Boeckxstaens,et al.  The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers , 2012, Alimentary pharmacology & therapeutics.

[13]  C. Gyawali.  High resolution manometry: the Ray Clouse legacy , 2012, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[14]  Y. Kinoshita,et al.  A Study on the Efficacy of Rebamipide for Patients with Proton Pump Inhibitor-Refractory Non-Erosive Reflux Disease , 2012, Digestive Diseases and Sciences.

[15]  A. Zwinderman,et al.  Effect of azithromycin on acid reflux, hiatus hernia and proximal acid pocket in the postprandial period , 2012, Gut.

[16]  R. Fass,et al.  Gastro-Oesophageal Reflux Disease , 2011, Drugs.

[17]  M. Vela,et al.  Refractory Heartburn: Comparison of Intercellular Space Diameter in Documented GERD vs. Functional Heartburn , 2011, The American Journal of Gastroenterology.

[18]  C. Gyawali,et al.  Value of preoperative esophageal function studies before laparoscopic antireflux surgery , 2011, Surgical Endoscopy.

[19]  T. Yoshikawa,et al.  Management of Recurrence of Symptoms of Gastroesophageal Reflux Disease: Synergistic Effect of Rebamipide with 15 mg Lansoprazole , 2010, Digestive Diseases and Sciences.

[20]  G. Boeckxstaens,et al.  The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD , 2009, Gut.

[21]  P. Sharma,et al.  Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed‐release formulation – results from two randomized controlled studies , 2009, Alimentary pharmacology & therapeutics.

[22]  H. Gooszen,et al.  Increased intragastric pressure gradients are involved in the occurrence of acid reflux in gastroesophageal reflux disease , 2009, Scandinavian journal of gastroenterology.

[23]  J. Pandolfino,et al.  Oesophageal peristaltic transition zone defects: real but few and far between , 2008, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[24]  J. Brill,et al.  American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. , 2008, Gastroenterology.

[25]  Gerald Holtmann,et al.  Asia‐Pacific consensus on the management of gastroesophageal reflux disease: Update , 2007, Journal of gastroenterology and hepatology.

[26]  R. Fass,et al.  Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn , 2007, Alimentary pharmacology & therapeutics.

[27]  J. Richter,et al.  ACG Practice Guidelines: Esophageal Reflux Testing , 2007, The American Journal of Gastroenterology.

[28]  S. Roman,et al.  Esophageal pH-Impedance Monitoring and Symptom Analysis in GERD: A Study in Patients off and on Therapy , 2006, The American Journal of Gastroenterology.

[29]  P. Whorwell,et al.  Treatment of non-cardiac chest pain: a controlled trial of hypnotherapy , 2006, Gut.

[30]  J. Tack,et al.  Characteristics and Clinical Relevance of Proximal Esophageal pH Monitoring , 2004, American Journal of Gastroenterology.

[31]  J. Dent,et al.  Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux , 2004, Gut.

[32]  J. Dent,et al.  Control of transient lower oesophageal sphincter relaxations and reflux by the GABAB agonist baclofen in patients with gastro-oesophageal reflux disease , 2002, Gut.

[33]  K. McColl,et al.  Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. , 2001, Gastroenterology.

[34]  R. Fass,et al.  Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro‐oesophageal reflux disease (GERD) who are resistant to conventional‐dose lansoprazole therapy—a prospective, randomized, multi‐centre study , 2000, Alimentary pharmacology & therapeutics.

[35]  L. Swanström,et al.  Diagnosis of Type-I hiatal hernia: a comparison of high-resolution manometry and endoscopy. , 2013, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[36]  R. Hunt,et al.  Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.